Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients

The identification of predictive biomarkers for antiangiogenic therapies remains an unmeet need. We hypothesized that the transcription factor Homeobox B9 (HOXB9) could be responsible for the tumor resistance to the anti-VEGF agent bevacizumab. HOXB9 expression and activation were measured in eight...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research Jg. 23; H. 15; S. 4312 - 4322
Hauptverfasser:	Carbone, Carmine, Piro, Geny, Simionato, Francesca, Ligorio, Francesca, Cremolini, Chiara, Loupakis, Fotios, Alì, Greta, Rossini, Daniele, Merz, Valeria, Santoro, Raffaela, Zecchetto, Camilla, Zanotto, Marco, Di Nicolantonio, Federica, Bardelli, Alberto, Fontanini, Gabriella, Tortora, Giampaolo, Melisi, Davide
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.08.2017
Schlagworte:	Adult Aged Angiopoietin-like Proteins - blood Animals Bevacizumab - administration & dosage Cell Line, Tumor Chemokine CXCL1 - blood Colorectal Neoplasms - blood Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Disease-Free Survival Drug Resistance, Neoplasm - genetics Female Gene Expression Regulation, Neoplastic - drug effects Homeodomain Proteins - genetics Humans Interleukin-8 - blood Male Mice Middle Aged Neoplasm Metastasis Prognosis Transforming Growth Factor beta - blood Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - genetics
ISSN:	1078-0432, 1557-3265
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!